

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klinman et al.

Application No. 10/523,273

Filed: January 31, 2005

Confirmation No. 2295

FILED VIA EFS ON

For: METHOD OF TREATING
INFLAMMATORY ARTHROPATHIES
WITH SUPPRESSORS OF CPG
OLIGONUCLEOTIDES

Examiner: Michelle S. Horning

Art Unit: 1648

Attorney Reference No. 4239-66339-03

SUBMITTED BY THE ELECTRONIC FILING SYSTEM (EFS)
COMMISSIONER FOR PATENTS

TERMINAL DISCLAIMER

The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, ("The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services") is the owner of the entire interest in the above-identified application. The assignment was recorded on January 31, 2005, (Reel 017330, Frames 0209-0218).

The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services hereby disclaims the terminal part of any patent granted on U.S. Patent Application No. 10/523,273, which would extend beyond the expiration date of the full statutory term of any patent granted on United States Patent Application No. 10/489,839, and hereby agrees that any patent so granted on U.S. Patent Application No. 10/523,273 shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent Application No. 10/489,839 or any patent granted thereon, this agreement to run with any patent granted on U.S. Patent Application No. 10/523,273 and to be binding upon the grantee, its successors or assigns.

The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services does not disclaim any terminal part of any patent granted on U.S. Patent Application No. 10/523,273 prior to the expiration date of the full statutory term of any patent granted on United States Patent Application No. 10/489,839, in the event that any patent granted on U.S. Patent Application No. 10/489,839 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above. If a patent does not grant on United States Patent Application No. 10/489,839, this terminal disclaimer has not effect.


I am empowered to act on behalf of The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The Government of the United States of America as
represented by the Secretary of the Department of
Health and Human Services

Feb 15, 2008

Date



Name

Teoh Li. Spec.

Title